Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

Blood

Volumn 101, Issue 12, 2003, Pages 4701-4707

  Bhatia, Ravi ^a   Holtz, Melissa ^b   Niu, Ning ^b   Gray, Rachel ^b   Snyder, David S ^b   Sawyers, Charles L ^b   Arber, Daniel A ^b   Slovak, Marilyn L ^b   Forman, Stephen J ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; STEM CELL;

EID: 0038454621     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2780     Document Type: Article

References (39)

1. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:209-213.
2. DeKlein A, Van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1982;300:765-767.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-827.
4. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
5. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792.
6. Lewis JM, Baskaran R, Taagepara S, Schwarz MA, Wang JYJ. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A. 1996;93:15174-15179.
7. Wang JYJ. Abl tyrosine kinase in signal transduction and cell cycle regulation. Curr Opin Gen Dev. 1993;3:35-43.
8. Lugo T, Pendergast A, Muller A, Witte O. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science. 1990;237:1079-1082.
9. McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol. 1991;11:1553-1565.
10. Muller AJ, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991;11:1785-1792.
11. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by BCR-ABL in vitro. Science. 1992;256:836-839.
12. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
13. Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
14. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
15. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
16. Druker BJ, Sawyers CS, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myelogenous leukemia and in acute lymphoblastic lymphoma with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
17. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
18. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
19. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
20. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
21. Branford S, Walsh S, Rudzki Z, et al. Imatinib produces significantly superior molecular responses compared to interferon plus low-dose Ara-C in patients with newly diagnosed chronic myelogenous leukemia [abstract]. Blood. 2001;100:96a.
22. Hughes T, Kaeda J, Branford S, et al. Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study [abstract]. Blood. 2002;100:93a.
23. Holtz M, Slovak M, Zhang F, Sawyers C, Forman S, Bhatia R. Gleevec (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792-3800.
24. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
25. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood. 1995;85:3636-3645.
26. Bhatia R, McGlave PB, Miller JS, Wissink S, Lin WN, Verfaillie CM. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Exp Hematol. 1997;25:980-991.
27. Michaeli J, Lerer I, Rachmilewitz A, Fibach E. Stimulation of proliferation of human myeloid leukemia cells in culture. Applications for cytogenetics analysis. Blood. 1986;68:790-793.
28. Gabrilove JL, Welte K, Harris P, et al. Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A. 1986;83:2478-2482.
29. Yunis JJ. New chromosome techniques in the study of human neoplasia. Hum Pathol. 1981;12:540-549.
30. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S. Karger; 1995.
31. Olavarria E, Kanfer E, Szydio R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560-1565.
32. Hochhaus A, Reiter A, Saubele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62-66.
33. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994;94:1383-1389.
34. Reiter A, Marley SB, Hochhaus A, et al. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. Br J Haematol. 1998;102:1271-1278.
35. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
36. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
37. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
38. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507-512.
39. Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A. Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood. 1996;88:1297-1305.